CAMP4 Therapeutics (CAMP) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.2M

Revenue (quarter)

$1.8M

Revenue growth (year over year)

+18.84%

Gross profit (trailing twelve months)

$4.2M

Gross margin

100.00%

Net income (trailing twelve months)

−$107.2M

Net income (quarter)

−$33.5M

Net income growth (year over year)

−166.39%

Net margin

−2543.74%

Return on equity

−545.85%

EPS (trailing twelve months)

−$2.31

Book value per share

−$0.01

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

100.74%

Payout ratio

—

Dividend yield

—

Company profile

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.

• Is CAMP4 Therapeutics (CAMP) profitable?

  No. CAMP4 Therapeutics reported a net loss of $107.2M over the trailing twelve months.

• How much revenue does CAMP4 Therapeutics (CAMP) make?

  CAMP4 Therapeutics generated $4.2M in revenue over the trailing twelve months, up 18.84% year over year.

• How do I buy stock in CAMP4 Therapeutics (CAMP)?

  CAMP trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.